CTx & liver transplantatison vs CTx in pts with unresectable CRC liver metastases at #ASCO24 🔎prospective trial TRANSMET, 94 pts 👉40% excluded, 9 drop out, 81% underwent LTx 👉mPFS 17.4 vs 6.4, 72% recurrence after LTx 👉5yr OS: 57% vs 13% 🧐potential cure for some pts,

That is some take home message!

And the party goes on!! Ablation equals resection for colorectal mets?

TransMet #ASCO24 game-changer ➡️definitively unresectable CRC LM ➡️chemo vs chemo &transplant ➡️heavily pre treated ➡️highly selected 👇🏻note %RASWT and left sided ➡️v impressive 5 yr OS 57 v13% ITT ➡️many recurrences rescued

#collision trial ASCO showing non-inferiority for thermal ablation both for local recurrence and OS! A major step for minimally invasive treatments! Congrats Martijn Meijerink Amsterdam UMC CIRSE @ihpba @ahpba @eahpba ESGAR

Orchestra: debulking debunked! 🇳🇱#ASCO24 - No benefit of debulking in 1st line pts with multi-organ metastatic CRC - median OS 27.5 vs 30 months; p=0.23

Amazing results, game changing trial! Ablation can now safely enter the main stage! Reto Bale Martijn Meijerink Kristoffer Lassen But local recurrence after liver resection was 14%? What do we think, liver surgeons? @eahpba @ahpba @ihpba

Is thermal ablation 🔥 equivalent to resection🔪for <3cm, well-located #CRLM Results of the 🇳🇱 COLLISION suggests so ASCO #ASCO24 OncoAlert OHSU Department of Surgery OHSU Knight Cancer Institute The Dotter Institute

ORCHESTRA 🎻 trial shows no benefit and increased morbidity to tumor debulking compared to SOC for #mCRC with multifocal visceral disease #ASCO24 OHSU Department of Surgery OHSU Knight Cancer Institute Divya Sood OncoAlert

CheckMate 8HW update #ASCO24 ➡️1st line ipi/nivo dMMR CRC vs chemo ➡️24 mth PFS 72% vs 14% ➡️24 mth PFS2 83% vs 52% ➡️manageable SEs Best option in 1st line

New from the Plenary Session at #ASCO24: ESOPEC helps settle debate on superiority of perioperative #chemo (FLOT) vs neoadjuvant chemoradiotherapy (CROSS) in esophageal cancer with 29-month improvement in OS with FLOT vs CROSS: brnw.ch/21wKmPS #ASCODailyNews #esocsm

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer #ASCO24 👉100% cCR, no relapse & no additional therapy 👉20 pts with sustained response of 12mo 👉ctDNA as an early marker of response 🧐Just amazing efficacy… ESMO - Eur. Oncology

New impact factors are out! Selected surgical journals 👇 JAMA Surg 15.7 BJS 8.6 Ann Surg 7.5 JACS 3.8 BJS Open 3.5 EJSO 3.5 ASO 3.5 Surgery 3.2 DCR 3.2 Colorec Dis 2.9 HPB 2.7 Tech Coloproct 2.7 Hernia 2.6 Scand J Surg 2.5 Surg Endosc 2.4 WJS 2.3 J GI Surg 2.2 Langenbeck’s 2.1

1st RCT comparing #robotic vs #laparoscopic hepatectomy for liver malignancies: #ROCNROLL trial published today together with our invited comment in The Lancet Reg Health-Europe Rutger-Jan Swijnenburg Tijs Hoogteijling authors.elsevier.com/sd/article/S26…

307 outpatient robotic liver resections. 2% complications; 1.6% readmissions; 6 centers. JHagendoorn Yuman Fong University of Washington Johns Hopkins Medicine City of Hope City of Hope Surgery #MoreCuresLessInvasive

🖋️Are you interested in learning the skills you need to publish surgical articles? Find out more about the online courses: 🆕Writing in Surgery 🆕Reviewing the Evidence Base in Surgery 🆕Editing in Surgery 🆕Evidence Based Surgery Postgraduate Certificate in Surgical Writing and

🌟 Exciting News! 🌟 E-AHPBA is forming an E-AHPBA Early Career Group to support & mirror the IHPBA ECG. We're seeking volunteers for our Steering Group. If you're committed and eager to make a difference, apply now! Deadline: Aug 2, 2024. #EarlyCareer IHPBA

Guess what I’m doing??